{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:46:52Z","timestamp":1791827212519,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06837-9","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:06:29Z","timestamp":1791824789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stage-specific prognostic value of PSA in prostate cancer: a multicentre KAMU-ON study"],"prefix":"10.1007","volume":"44","author":[{"given":"Hiroaki","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Machioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Toriumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Kamijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Kadomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yaegashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Shigehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Kadono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"11","key":"6837_CR1","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/iju.15545","volume":"31","author":"Y Kohjimoto","year":"2024","unstructured":"Kohjimoto Y, Uemura H, Yoshida M, Hinotsu S, Takahashi S, Takeuchi T et al (2024) Japanese clinical practice guidelines for prostate cancer 2023. Int J Urol 31(11):1180\u20131222","journal-title":"Int J Urol"},{"key":"6837_CR2","doi-asserted-by":"crossref","unstructured":"Eastham JA, Barocas DA, Chu CE, Morgans AK, Rodrigues G, Kirkby E et al (2026) Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline Amendment The Journal of urology. 2026:101097ju0000000000005060","DOI":"10.1097\/JU.0000000000005060"},{"key":"6837_CR3","unstructured":"European Association of Urology EAU Guidelines on Prostate Cancer Available at: https:\/\/uroweb.org\/guidelines\/prostate-cancer2026 [Available from: https:\/\/uroweb.org\/guidelines\/prostate-cancer"},{"key":"6837_CR4","unstructured":"Network NCC (2026) NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5: National Comprehensive Cancer Network; [Available from: https:\/\/www.nccn.org"},{"issue":"10","key":"6837_CR5","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/pros.22985","volume":"75","author":"K Izumi","year":"2015","unstructured":"Izumi K, Ikeda H, Maolake A, Machioka K, Nohara T, Narimoto K et al (2015) The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels. Prostate 75(10):1034\u20131042","journal-title":"Prostate"},{"issue":"3","key":"6837_CR6","doi-asserted-by":"publisher","first-page":"119e19","DOI":"10.1016\/j.urolonc.2015.09.014","volume":"34","author":"AD Falchook","year":"2016","unstructured":"Falchook AD, Martin NE, Basak R, Smith AB, Milowsky MI, Chen RC (2016) Stage at presentation and survival outcomes of patients with Gleason 8\u201310 prostate cancer and low prostate-specific antigen. Urol Oncol 34(3):119e19\u2013119e26","journal-title":"Urol Oncol"},{"issue":"1","key":"6837_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/cncr.29691","volume":"122","author":"BA Mahal","year":"2016","unstructured":"Mahal BA, Aizer AA, Efstathiou JA, Nguyen PL (2016) Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. Cancer 122(1):78\u201383","journal-title":"Cancer"},{"issue":"2","key":"6837_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.eururo.2018.01.043","volume":"74","author":"BA Mahal","year":"2018","unstructured":"Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V et al (2018) Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 74(2):146\u2013154","journal-title":"Eur Urol"},{"key":"6837_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2022.12.017","volume":"181","author":"CD Fankhauser","year":"2023","unstructured":"Fankhauser CD, Parry MG, Ali A, Cowling TE, Nossiter J, Sujenthiran A et al (2023) A low prostate specific antigen predicts a worse outcome in high but not in low\/intermediate-grade prostate cancer. Eur J Cancer 181:70\u201378","journal-title":"Eur J Cancer"},{"issue":"1","key":"6837_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.euf.2018.08.024","volume":"6","author":"J Wang","year":"2020","unstructured":"Wang J, Abudurexiti M, Shao N, Wei Y, Zhu Y, Ye DW (2020) The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma. Eur Urol Focus 6(1):53\u201362","journal-title":"Eur Urol Focus"},{"issue":"1","key":"6837_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/JS9.0000000000001884","volume":"111","author":"Z Liu","year":"2025","unstructured":"Liu Z, Hong P, He J, Li Z, Wu J, Qiu L et al (2025) Favorable prostate-specific antigen levels correlate with a worse prognosis in high-grade prostate cancer: a population-based analysis. Int J Surg 111(1):807\u2013817","journal-title":"Int J Surg"},{"issue":"5","key":"6837_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/pros.24664","volume":"84","author":"I de Kouchkovsky","year":"2024","unstructured":"de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R (2024) Diagnosis and management of neuroendocrine prostate cancer. Prostate 84(5):426\u2013440","journal-title":"Prostate"},{"issue":"21","key":"6837_CR13","doi-asserted-by":"publisher","first-page":"31384","DOI":"10.18632\/oncotarget.8915","volume":"7","author":"R Stuchbery","year":"2016","unstructured":"Stuchbery R, Macintyre G, Cmero M, Harewood LM, Peters JS, Costello AJ et al (2016) Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression. Oncotarget 7(21):31384\u201331392","journal-title":"Oncotarget"},{"issue":"2","key":"6837_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H (2021) Clinical and Biological Features of Neuroendocrine Prostate Cancer. Curr Oncol Rep 23(2):15","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"6837_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1590\/s1677-5538.ibju.2018.0143","volume":"45","author":"H Iwamoto","year":"2019","unstructured":"Iwamoto H, Izumi K, Kadono Y, Mizokami A (2019) Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20\u2013100 ng \/ mL. Int Braz J Urol 45(1):61\u20137","journal-title":"Int Braz J Urol"},{"issue":"8","key":"6837_CR16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00432-014-1681-8","volume":"140","author":"K Izumi","year":"2014","unstructured":"Izumi K, Lin WJ, Miyamoto H, Huang CK, Maolake A, Kitagawa Y et al (2014) Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level. J Cancer Res Clin Oncol 140(8):1413\u20131419","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"6837_CR17","doi-asserted-by":"publisher","first-page":"e1091","DOI":"10.1016\/j.clgc.2019.05.029","volume":"17","author":"H Kodama","year":"2019","unstructured":"Kodama H, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S et al (2019) Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer. Clin Genitourin Cancer 17(6):e1091\u2013e8","journal-title":"Clin Genitourin Cancer"},{"issue":"13","key":"6837_CR18","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/cncr.33503","volume":"127","author":"DW Kim","year":"2021","unstructured":"Kim DW, Chen MH, Wu J, Huland H, Graefen M, Tilki D et al (2021) Prostate-specific antigen levels of =4 and 4 ng\/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer. Cancer 127(13):2222\u20132228","journal-title":"Cancer"},{"key":"6837_CR19","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.19823","volume":"13","author":"J Mei","year":"2025","unstructured":"Mei J, Zhu G, Yao Y, Guan F, Sun L, Zhang G (2025) Comparison of survival in patients with low vs. intermediate prostate-specific antigen concentrations and development of a nomogram: a surveillance, epidemiology and end results program database study with external validation on a Chinese cohort. PeerJ 13:e19823","journal-title":"PeerJ"},{"key":"6837_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijsu.2020.02.024","volume":"76","author":"P Song","year":"2020","unstructured":"Song P, Yang B, Peng Z, Zhou J, Ren Z, Fang K et al (2020) Reduced cancer-specific survival of low prostate-specific antigen in high-grade prostate cancer: A population-based retrospective cohort study. Int J Surg 76:64\u201368","journal-title":"Int J Surg"},{"key":"6837_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci164611","author":"F Karzai","year":"2022","unstructured":"Karzai F, Madan RA (2022) Deciphering the enigma of neuroendocrine prostate cancer. J Clin Invest. https:\/\/doi.org\/10.1172\/jci164611","journal-title":"J Clin Invest"},{"issue":"1","key":"6837_CR22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12672-026-04482-7","volume":"17","author":"EF Giunta","year":"2026","unstructured":"Giunta EF, Schepisi G, Bleve S, Serra R, Brighi N, Torresan I et al (2026) Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives. Discov Oncol 17(1):457","journal-title":"Discov Oncol"},{"issue":"4","key":"6837_CR23","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.21873\/anticanres.15699","volume":"42","author":"H Iwamoto","year":"2022","unstructured":"Iwamoto H, Nakagawa R, Makino T, Kadomoto S, Yaegashi H, Nohara T et al (2022) Treatment Outcomes in Neuroendocrine Prostate Cancer. Anticancer Res 42(4):2167\u20132176","journal-title":"Anticancer Res"},{"issue":"6","key":"6837_CR24","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.euf.2022.03.009","volume":"8","author":"I Tsaur","year":"2022","unstructured":"Tsaur I, van den Bergh RCN, Soeterik T, Thomas A, Brandt MP, Zattoni F et al (2022) Predictors of unfavorable pathology in patients with incidental (pT1a-T1b) prostate cancer. Eur Urol Focus 8(6):1599\u2013606","journal-title":"Eur Urol Focus"},{"issue":"5","key":"6837_CR25","doi-asserted-by":"publisher","first-page":"e2111092","DOI":"10.1001\/jamanetworkopen.2021.11092","volume":"4","author":"MT King","year":"2021","unstructured":"King MT, Chen MH, Collette L, Neven A, Bolla M, D\u2019Amico AV (2021) Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Netw Open 4(5):e2111092","journal-title":"JAMA Netw Open"},{"issue":"8","key":"6837_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/iju.70617","volume":"33","author":"H Iwamoto","year":"2026","unstructured":"Iwamoto H, Izumi K, Machioka K, Toriumi R, Shima T, Nozaki M et al (2026) Stage-specific temporal trends in treatment patterns and overall survival in prostate cancer: a multicentre real-world cohort study from KAMU-ON. Int J Urol 33(8):e70617","journal-title":"Int J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06837-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06837-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06837-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:06:31Z","timestamp":1791824791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06837-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6837"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06837-9","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"6 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have competing interests as detailed in the Declaration of Interest Statement.\u00a0All authors have completed the Declaration of Interest form. Hiroaki Iwamoto reports honoraria from Janssen and travel support from Novartis Pharma. Kouji Izumi reports clinical trial involvement with AstraZeneca, MSD, Janssen, Bayer, Novartis, Pfizer, Chugai, and AbbVie; honoraria from AstraZeneca, Janssen, Bayer, Novartis, Astellas, Sysmex, Ono Pharmaceutical, and Bristol-Myers Squibb; and consulting fees from Janssen.Kazuaki Machioka reports no conflicts of interest. Ren Toriumi reports no conflicts of interest. Takashi Shima reports honoraria from Ono Pharmaceutical, Janssen, Sanofi, and Eisai. Masakazu Nozaki reports no conflicts of interest. Tomohiro Hori reports travel support from Novartis Pharma.Takahiro Inaba reports no conflicts of interest. Ryunosuke Nakagawa reports honoraria from Ono Pharmaceutical. Taiki Kamijima reports honoraria from AstraZeneca and advisory board participation for Kissei Pharmaceutical. Suguru Kadomoto reports no conflicts of interest. Tomoyuki Makino reports no conflicts of interest. Renato Naito reports honoraria from Mediphysics, Ono Pharmaceutical, and MSD, and travel support from Novartis Pharma. Hiroshi Yaegashi reports honoraria from Janssen Pharmaceutical K.K., AstraZeneca, Bayer, Astellas, MSD, Ono Pharmaceutical, Bristol-Myers Squibb, Beckman Coulter, Kissei Pharmaceutical, and Eisai. Kazuyoshi Shigehara reports honoraria from Nippon Shinyaku, MSD, Teleflex Japan, Meiji Seika, Kissei Pharmaceutical, and Tsumura. Takahiro Nohara reports honoraria from Nippon Kayaku, Sysmex, MSD, and Astellas; consulting\/advisory roles; research funding from SBI Pharma and Sysmex; grants from the Japanese Society of Endourology and Robotics; and travel support. Tohru Miyagi reports no conflicts of interest. Chikashi Seto reports no conflicts of interest. Yoshifumi Kadono reports honoraria from AstraZeneca, Astellas, Eisai, Ono Pharmaceutical, Kissei, Johnson & Johnson, Bayer, Bristol-Myers Squibb, Merck Biopharma, and Janssen. Atsushi Mizokami reports clinical trial involvement with Pfizer, AstraZeneca, and Amgen, and honoraria from Astellas, AstraZeneca, Bayer, Janssen, PDR Pharma, Johnson & Johnson, Sanofi, and Novartis.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used ChatGPT (OpenAI) to assist with language editing. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":2,"name":"Ethics","label":"Generative AI and AI-assisted technologies","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"740"}}